Data On Neoadjuvant Talazoparib
Hope Rugo, M.D., University Of California San Francisco discusses Data On Neoadjuvant Talazoparib. At ESMO Oncology Conference - Munich, Germany On October 19, 2018.
Author: Cancer-News
Added: 10/30/2018 (Source: Oncology Tube)
Source: Oncology Tube - October 30, 2018 Category: Cancer & Oncology Source Type: podcasts
TRITON3 Randomized Study
Josep Piulats, M.D., PhD, Catalan Cancer Institute discusses TRITON3 Randomized Study. At ESMO Oncology Conference - Munich, Germany On October 19, 2018.<br />
Author: Cancer-News
Added: 10/30/2018 (Source: Oncology Tube)
Source: Oncology Tube - October 30, 2018 Category: Cancer & Oncology Source Type: podcasts
TRITON2 Trial, Rucaparib PARP Inhibitor Data
Josep Piulats, M.D., PhD, Catalan Cancer Institute discusses TRITON2 Trial, Rucaparib PARP Inhibitor Data. At ESMO Oncology Conference - Munich, Germany On October 19, 2018.<br />
Author: Cancer-News
Added: 10/30/2018 (Source: Oncology Tube)
Source: Oncology Tube - October 30, 2018 Category: Cancer & Oncology Source Type: podcasts
TRITON2 Trial Results
Josep Piulats, M.D., PhD, Catalan Cancer Institute discusses TRITON2 Trial Results. At ESMO Oncology Conference - Munich, Germany On October 19, 2018.
Author: Cancer-News
Added: 10/30/2018 (Source: Oncology Tube)
Source: Oncology Tube - October 30, 2018 Category: Cancer & Oncology Source Type: podcasts
SL-701 Availability
David Peereboom, M.D., Cleveland Clinic Discusses SL-701 Availability. At ESMO Oncology Conference - Munich, Germany On October 19, 2018.
Author: Cancer-News
Added: 10/30/2018 (Source: Oncology Tube)
Source: Oncology Tube - October 30, 2018 Category: Cancer & Oncology Source Type: podcasts
New Plans With SL-701 Drug
David Peereboom, M.D., Cleveland Clinic Discusses New Plans With SL-701 Drug. At ESMO Oncology Conference - Munich, Germany On October 19, 2018.<br />
Author: Cancer-News
Added: 10/30/2018 (Source: Oncology Tube)
Source: Oncology Tube - October 30, 2018 Category: Cancer & Oncology Source Type: podcasts
How SL-701 Was Generated
David Peereboom, M.D., Cleveland Clinic Discusses How SL-701 Was Generated. At ESMO Oncology Conference - Munich, Germany On October 19, 2018.
Author: Cancer-News
Added: 10/30/2018 (Source: Oncology Tube)
Source: Oncology Tube - October 30, 2018 Category: Cancer & Oncology Source Type: podcasts
Whats On Deck For Lurbinectedin
Pascal Besman Chief Operating Officer at PharmaMar discusses Whats On Deck For Lurbinectedin. At ESMO Oncology Conference - Munich, Germany On October 19, 2018.<br />
Author: Cancer-News
Added: 10/30/2018 (Source: Oncology Tube)
Source: Oncology Tube - October 30, 2018 Category: Cancer & Oncology Source Type: podcasts
Upcoming SCLC Data
Pascal Besman Chief Operating Officer at PharmaMar discusses Upcoming SCLC Data. At ESMO Oncology Conference - Munich, Germany On October 19, 2018.<br />
Author: Cancer-News
Added: 10/30/2018 (Source: Oncology Tube)
Source: Oncology Tube - October 30, 2018 Category: Cancer & Oncology Source Type: podcasts
Progress In SCLC Vs. NSCLC
Pascal Besman Chief Operating Officer at PharmaMar discusses Progress In SCLC Vs. NSCLC. At ESMO Oncology Conference - Munich, Germany On October 19, 2018.<br />
Author: Cancer-News
Added: 10/30/2018 (Source: Oncology Tube)
Source: Oncology Tube - October 30, 2018 Category: Cancer & Oncology Source Type: podcasts
Lurbinectedin Data Presented This Year
Pascal Besman Chief Operating Officer at PharmaMar discusses Lurbinectedin Data Presented This Year. At ESMO Oncology Conference - Munich, Germany On October 19, 2018.
Author: Cancer-News
Added: 10/30/2018 (Source: Oncology Tube)
Source: Oncology Tube - October 30, 2018 Category: Cancer & Oncology Source Type: podcasts
IO Likely In 1st Line SCLC
Pascal Besman Chief Operating Officer at PharmaMar discusses IO Likely In 1st Line SCLC. At ESMO Oncology Conference - Munich, Germany On October 19, 2018.<br />
Author: Cancer-News
Added: 10/30/2018 (Source: Oncology Tube)
Source: Oncology Tube - October 30, 2018 Category: Cancer & Oncology Source Type: podcasts
Emerging New Agents In SCLC
Pascal Besman Chief Operating Officer at PharmaMar discusses Emerging New Agents In SCLC. At ESMO Oncology Conference - Munich, Germany On October 19, 2018.
Author: Cancer-News
Added: 10/30/2018 (Source: Oncology Tube)
Source: Oncology Tube - October 30, 2018 Category: Cancer & Oncology Source Type: podcasts
Current Standard Of Care In SCLC
Pascal Besman Chief Operating Officer at PharmaMar discusses Current Standard Of Care In SCLC. At ESMO Oncology Conference - Munich, Germany On October 19, 2018.
Author: Cancer-News
Added: 10/30/2018 (Source: Oncology Tube)
Source: Oncology Tube - October 30, 2018 Category: Cancer & Oncology Source Type: podcasts
Efficacy & amp; Safety Of M7824
Byoung Chul Cho, M.D., Yonsei Cancer Center discusses Efficacy & Safety Of M7824. At ESMO Oncology Conference - Munich, Germany On October 19, 2018.
Author: Cancer-News
Added: 10/29/2018 (Source: Oncology Tube)
Source: Oncology Tube - October 29, 2018 Category: Cancer & Oncology Source Type: podcasts
